Diagnostic & mechanistic studies
tested Skeletal muscle HN protein levels, serum HN protein levels, correlation with 2h glucose loading test
result Skeletal muscle HN protein +35% after 12 wks resistance training in prediabetic males (n=55); no serum change; serum HN correlated with 2h glucose improvements in RT group.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested MMSE scores and serum Humanin levels before and after 12-week HBO therapy
result HBO group showed significantly higher MMSE scores and serum Humanin levels vs control after 12 weeks (p<0.05); Humanin correlated with MMSE (r=0.409).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested blood humanin (HN) levels as a biomarker alongside brain MRI, BDNF, IGF-1, FGF21, GDF-15, oxidative stress, and inflammation markers
result Humanin measured as a blood biomarker in a 12-week WBRT RCT (n=24); abstract reports increases in BDNF, IGF-1, FGF21, GDF-15 but does not explicitly state humanin result.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested serum MOTS-c levels correlated with OSA severity, AHI, BMI, and HOMA-IR
result MOTS-c significantly lower in OSA vs controls (p<0.000); negative correlation with AHI (r=-0.492) and BMI (r=-0.382); independently associated with AHI, BMI, HOMA-IR in regression (p<0.01).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested Plasma humanin and MOTS-c levels before and at 30 min and 3h post-exercise
result Acute endurance exercise (45 min cycling at 70% VO2max) significantly elevated circulating humanin; MOTS-c trended upward. Resistance exercise did not raise MDP levels. HN correlated with MOTS-c and age at rest.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested circulating humanin levels, TBARS (oxidative stress), MACE prediction
result Humanin lower in angina (124.22 vs 157.77 pg/ml) and MI (67.17 pg/ml) vs controls; low humanin = independent risk factor for MI; predicts MACE in angina group.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested Exacerbation risk, malnutrition, 6-minute walk distance, future moderate/severe exacerbations over 12 months
result High serum HN associated with exacerbation risk (OR 2.798), malnutrition (OR 6.645), reduced 6MWD (OR 0.995), future moderate exacerbations (HR 1.826) and severe exacerbations (HR 3.445).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested Humanin mRNA expression in adrenal tissue and serum humanin levels
result Significant reduction in humanin mRNA expression in ACC patients vs controls; no significant change in serum humanin levels; positive correlation with age, negative with tumor size and LDL.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested serum humanin levels before, during, and after radiotherapy measured by ELISA
result Humanin levels markedly declined in breast cancer patients (P<0.001) but were not significantly elevated in lung cancer patients; radiotherapy did not modify humanin levels in either group.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested Serum humanin levels; humanin expression in ex vivo human growth plate cartilage exposed to IBD serum or TNF
result Serum humanin significantly decreased in IBD children vs. healthy controls; IBD serum and TNF alone suppressed humanin, PCNA, SOX9, and TRAF2 in ex vivo human growth plates.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested Primary composite: all-cause mortality + non-fatal CV events; secondary: all-cause mortality alone
result U-shaped association: very low (<759.5 pg/mL) and very high Humanin both associated with elevated HR (5.84–4.50) for composite CV/mortality endpoint; baseline level did not differ by endpoint (p=0.69/0.76).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested Serum humanin and MOTS-c levels, nitrosative stress (NO, 3-nitrotyrosine), ferroptosis parameters (GPX4, ACSL4, TFRC)
result SGLT2 inhibitors had no marked effect on humanin levels but significantly augmented MOTS-c. Nitrosative stress markers reduced; GPX4 elevated, ACSL4 suppressed (P<0.001).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested serum humanin levels measured by ELISA; correlation with endoglin, VPO1, MOTS-c, miR-200c
result No significant difference in humanin levels between preeclampsia and control groups; positive correlation with endoglin (r=0.421, p<0.01) in preeclamptic group.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested serum MOTS-c levels, maximal oxygen uptake
result Marathon runners showed higher serum MOTS-c and aerobic capacity vs sedentary; MOTS-c correlated with VO2max, body fat status, and training load.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested flow-mediated pulse amplitude tonometry (Ln-RHI); survival
result Higher humanin levels associated with better endothelial function (OR=0.9774, p=0.0196) and improved survival (Kaplan-Meier, p significant).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested Serum MOTS-c levels and their correlation with OSA severity, BMI, AHI, and ODI
result MOTS-c levels inversely correlated with OSA severity, AHI, and ODI; lower levels in more severe OSA; OSA severity was independent predictor after ANCOVA controlling for BMI.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested Diagnostic accuracy of circulating Humanin, MOTS-c, GAS5, miR-21, miR-103 for prostate disease classification
result Humanin downregulated in PL and PCa vs BPH. Plasma-only model (Humanin+GAS5+MOTS-c) reached 95% cross-validated classification accuracy across clinical groups.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested Serum humanin levels and skeletal muscle humanin expression (Western blot of vastus lateralis biopsy)
result Serum humanin lower in PCOS vs controls (474.9 vs 672.3 pg/mL, p<0.001); no difference in skeletal muscle humanin (p=0.71); negative correlations with testosterone, insulin, cholesterol, LDL, triglycerides.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested serum humanin concentration; ROC curve diagnostic performance
result Serum humanin significantly elevated in breast cancer vs controls (p<0.001); ROC sensitivity 78.7%, specificity 62.9%.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested Serum humanin-like 3 levels as a biomarker to differentiate MS-SCON from NMOSD
result MS-SCON had significantly higher humanin-like 3 than other groups; ROC cut-off 5.26 ng/ml discriminated MS-SCON from NMOSD with 66.7% sensitivity and 90% specificity.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested Cardiovascular morbidity and mortality (fatal or non-fatal CV events requiring hospitalization) over 24 months
result Adding Humanin improved CVMM model AUC by ΔAUC 0.083–0.109, R² gain 9–15%, NRI 8–27.9%, IDI 4.4–7.3% across all 5 models; curvilinear risk (<364 or >778 pg/mL elevated risk).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested circulating Humanin and SHMOOSE levels; oxidative stress markers sNox2-dp and 8-iso-PGF2α
result High Med-Diet adherence associated with higher Humanin (p=0.045); Humanin inversely associated with sNox2-dp (β=-0.302, p=0.040) and 8-iso-PGF2α (p=0.049).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested serum MOTS-c levels and m.1382A>C polymorphism association with PCOS and metabolic parameters
result Mean serum MOTS-c higher in PCOS vs controls but not significant (p=0.059); no significant association with metabolic parameters (p>0.05); all participants wild-type A/A for m.1382A>C.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested Correlations between serum/urine/dialysate MOTS-c and AOPPs, carotid-femoral PWV, LV systolic function, and blood pressure
result uMOTS-c inversely correlated with AOPPs (R=-0.592, p=0.012), positively with PWV (R=0.708, p=0.001); dMOTS-c inversely with PWV (R=-0.717, p=0.019) and BP (R=-0.5, p<0.01).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Preclinical / mechanistic research
tested mouse · Chronic treatment with the mitochondrial peptide humanin prevents age-related myocardial fibrosis in mice.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested mouse · Earlier changes in mice after D-galactose treatment were improved by mitochondria derived small peptide MOTS-c.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · Humanin Alleviates Insulin Resistance in Polycystic Ovary Syndrome: A Human and Rat Model-Based Study.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · Effects of N-Acetylcysteine on Humanin and Endostatin in Rats Exposed to Formaldehyde.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested mouse · Humanin attenuates metabolic, toxic, and traumatic neuropathic pain in mice by protecting against oxidative stress and increasing inflammatory cytokine.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested mouse · Humanin-G Ameliorates Hemorrhage-Induced Acute Lung Injury in Mice Through AMPKα1-Dependent and -Independent Mechanisms.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · Exercise Improves Cardiac Dysfunction in D-Galactose-Treated Rats by Regulation of IGF-1-Humanin Pathway.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested mouse · Humanin improves bone health in a glucocorticoid-treated mouse model of Duchenne muscular dystrophy.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested mouse · Mitochondria-derived peptide MOTS-c alleviates hyperoxia-induced bronchopulmonary dysplasia in neonatal mice by activating Nrf2 pathway.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested mouse · Humanin Restores Metabolic Hormone Homeostasis of Leptin, Ghrelin, Irisin and Asprosin in Streptozotocin-Induced Diabetic Mice.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested mouse · Humanin ameliorates diabetes-induced testicular damage in a streptozotocin-induced mouse model.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · Humanin peptide ameliorates reproductive dysfunction and restores neuroendocrine mechanisms in SSRI-treated male rats.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested Comprehensive in vitro profiling of traditional and emerging stimulants at monoamine transporters and the 5HT2A receptor
result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.
Preclinical / mechanistic research
tested Humanin G (HNG) protects age-related macular degeneration (AMD) transmitochondrial ARPE-19 cybrids from mitochondrial and cellular damage.
result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.
Preclinical / mechanistic research
tested Neuron-derived extracellular vesicles in blood reveal effects of exercise in Alzheimer's disease.
result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.
Preclinical / mechanistic research
tested Humanin reduces nucleus pulposus cells ferroptosis to alleviate intervertebral disc degeneration: An in vitro and in vivo study.
result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.
Preclinical / mechanistic research
tested Exploring the therapeutic potential of MOTS-c in age-related macular degeneration: from cellular responses to patient-derived cybrids.
result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.
Preclinical / mechanistic research
tested Mitochondrial derived peptide humanin improved semen quality, semen freezability, antioxidant status and in-vitro fertility in crossbred bull.
result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.
Preclinical / mechanistic research
tested Comprehensive in vitro profiling of traditional and emerging stimulants at monoamine transporters and the 5-HT<sub>2A</sub> receptor.
result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.